Introduction {#s1}
============

MicroRNAs (miRNAs) are tiny noncoding RNAs that act as posttranscriptional gene regulatory elements [@pone.0080570-Sand1]. Specifically, miRNAs act by binding to the 3'-untranslated region of target genes and to consequently down-regulate their expression [@pone.0080570-Filipowicz1]. MiRNAs are important players in carcinogenesis [@pone.0080570-Garzon1].

Genetic factors, such as single nucleotide polymorphisms (SNPs), may contribute to carcinogenesis [@pone.0080570-Shen1]. The SNPs in the genomic miRNA sequences could influence miRNA-dependent regulation, affect the final level and function of miRNAs and alter consequently tumor susceptibility [@pone.0080570-Nicoloso1].

Members of the miR-34 family are direct p53 targets, and their expression is directly induced by p53 in response to DNA damage or oncogenic stress [@pone.0080570-Bommer1]. In previous studies in colorectal cancer [@pone.0080570-Toyota1], oral cancer [@pone.0080570-Kozaki1] and malignant melanoma [@pone.0080570-Lujambio1], down-regulation of mir-34b/c by methylation was found. *Hsa-miR-34b/c* rs4938723 polymorphism is located within the CpG island of pri-miR-34b/c, and might be the predicted binding site for GATA-X transcription factors [@pone.0080570-Son1]. *Hsa-miR-34b/c* rs4938723 T\>C polymorphism was associated with the risk of nasopharyngeal carcinoma [@pone.0080570-Li1], hepatocellular carcinoma [@pone.0080570-Han1], colorectal cancer [@pone.0080570-Gao1] and breast cancer survival [@pone.0080570-Bensen1].

Besides *hsa-miR-34b/c* rs4938723 T\>C, *pri-miR-124-1* rs531564 C\>G, *pre-miR-125a* rs12975333 G\>T and *hsa-miR-423* rs6505162 C\>A were also associated with the risk of different types of cancers. The rs531564 C\>G SNP in *pri-miR-124-1* was associated with an increased risk of bladder cancer [@pone.0080570-Yang1] and esophageal cancer in males [@pone.0080570-Ye1]. The *pre-miR-125a* rs12975333 G\>T polymorphism was a founder mutation specific to the Antwerp area and associated with high risk for breast cancer [@pone.0080570-Peterlongo1]. *Hsa-miR-423* rs6505162 C\>A polymorphism was associated with reduced breast cancer risk [@pone.0080570-Smith1]. *Hsa-miR-423* rs6505162 C\>A polymorphism was also significantly associated with both the overall survival and the recurrence-free survival of colorectal cancer [@pone.0080570-Xing1].

We previously investigated *miR-196a2* rs11614913 T\>C, *miR-146a* rs2910164 C\>G, *miR-499* rs3746444 T\>C, *miR-26a-1* rs7372209 C\>T and *miR-27a* rs895819 T\>C SNPs and esophageal squamous cell carcinoma (ESCC) risk in 380 cancer cases and 380 controls [@pone.0080570-Wei1]. We found *miR-196a2* rs11614913 T\>C might contribute to decreased ESCC risk among women patients and patients who never smoking or drinking [@pone.0080570-Wei1]. Now, the objective of this investigation was to evaluate the association between *hsa-miR-34b/c* rs4938723 T\>C, *pri-miR-124-1* rs531564 C\>G, *pre-miR-125a* rs12975333 G\>T and *hsa-miR-423* rs6505162 C\>A genotypes and ESCC risk. We performed genotyping analyses for the four *miRNA* SNPs with 629 ESCC cases and 686 controls in a Chinese population.

Materials and Methods {#s2}
=====================

Ethical approval of the study protocol {#s2a}
--------------------------------------

This hospital-based case-control study was approved by the Review Board of Jiangsu University (Zhenjiang, China). We have complied with the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects and/or animals. All subjects provided written informed consent to be included in the study.

Patients and Controls {#s2b}
---------------------

629 subjects with esophageal cancer were consecutively recruited from the Affiliated People's Hospital of Jiangsu University and Affiliated Hospital of Jiangsu University (Zhenjiang, China) between October 2008 and December 2010. Diagnosis was done by biopsy and all cases of esophageal cancer were ESCC. The exclusion criteria were patients who previously had: cancer; any metastasized cancer; radiotherapy or chemotherapy. The 686 controls were patients without cancer frequency-matched to the cases with regard to age (±5 years) and sex recruited from the two hospitals mentioned above during the same time period. Most of the controls were admitted to the hospitals for the treatment of trauma.

Each subject was personally questioned by trained interviewers using a pre-tested questionnaire to obtain information on demographic data (e.g., age, sex) and related risk factors (including tobacco smoking and alcohol consumption). After the interview, 2-mL samples of venous blood were collected from each subject. Individuals who smoked one cigarette per day for \>1 year were defined as "smokers". Subjects who consumed ≥3 alcoholic drinks a week for \>6 months were considered to be "alcohol drinkers".

Isolation of DNA and genotyping by Ligation Detection Reaction {#s2c}
--------------------------------------------------------------

Blood samples were collected from patients using Vacutainers and transferred to tubes lined with ethylenediamine tetra-acetic acid (EDTA). Genomic DNA was isolated from whole blood with the QIAamp DNA Blood Mini Kit (Qiagen, Berlin, Germany) [@pone.0080570-Gu1]. Sample DNA were amplified by PCR according to the manufacturer's recommendations. The samples were genotyped using the Ligation Detection Reaction (LDR) method with technical support from the Shanghai Biowing Applied Biotechnology Company as previously described [@pone.0080570-Chen1]. For quality control, repeated analyses were done for 160 (12.17%) randomly selected samples with high DNA quality.

Statistical Analyses {#s2d}
--------------------

Differences in the distributions of demographic characteristics, selected variables, and genotypes of the *hsa-miR-34b/c* rs4938723 T\>C, *pri-miR-124-1* rs531564 C\>G, *pre-miR-125a* rs12975333 G\>T and *hsa-miR-423* rs6505162 C\>A variants between the cases and controls were evaluated using student t test and the *χ* ^2^ test. The associations between the four SNPs and risk of ESCC were estimated by computing the ORs and their 95% CIs using logistic regression analyses for crude ORs and adjusted ORs when adjusting for age, sex, smoking and drinking status. The Hardy-Weinberg equilibrium (HWE) was tested by a goodness-of-fit *χ* ^2^ test to compare the observed genotype frequencies to the expected ones among the control subjects. All statistical analyses were performed with SAS 9.1.3 (SAS Institute, Cary, NC, USA).

Results {#s3}
=======

Characteristics of the study population {#s3a}
---------------------------------------

Characteristics of cases and controls included in the study are summarized in [Table 1](#pone-0080570-t001){ref-type="table"}. The cases and controls appeared to be adequately matched on age and sex as suggested by the *χ* ^2^ tests (*p* = 0.541 and *p* = 0.185, respectively). As shown in [Table 1](#pone-0080570-t001){ref-type="table"}, significant difference was detected on smoking status between the cases and the controls (*p* \< 0.001), and drinking rate was higher in ESCC patients than in control subjects (*p* \< 0.001). The primary information for four genotyped SNPs was in [Table 2](#pone-0080570-t002){ref-type="table"}. The genotyping success rate is ranging from 95.13% to 96.81% in all 1315 samples. The concordance rates of repeated analyses were 100% for all four SNPs. Minor allele frequency (MAF) in our controls was similar to MAF for Chinese in database for all four SNPs ([Table 2](#pone-0080570-t002){ref-type="table"}). The observed genotype frequencies for *hsa-miR-34b/c* rs4938723 T\>C, *pri-miR-124-1* rs531564 C\>G and *hsa-miR-423* rs6505162 C\>A polymorphisms in the controls were in HWE (*p* = 0.675, *p* = 0.400 and *p* = 0.299) except *pre-miR-125a* rs12975333 G\>T (not available) ([Table 2](#pone-0080570-t002){ref-type="table"}).

10.1371/journal.pone.0080570.t001

###### Distribution of selected demographic variables and risk factors in ESCC cases and controls.

![](pone.0080570.t001){#pone-0080570-t001-1}

  Variable                     Cases (n = 629) n %   Controls (n = 686) n %   *p* [a](#nt101){ref-type="table-fn"}          
  --------------------------- --------------------- ------------------------ -------------------------------------- ------- -------------
  **Age (years)** mean ± SD       62.85 (±8.13)          62.58 (±7.89)                       0.541                          
  **Age (years)**                                                                                                               0.155
  \< 63                                310                   49.28                            365                    53.21  
  ≥ 63                                 319                   50.72                            321                    46.79  
  **Sex**                                                                                                                       0.185
  Male                                 444                   70.59                            461                    67.20  
  Female                               185                   29.41                            225                    32.80  
  **Tobacco use**                                                                                                            **\<0.001**
  Never                                355                   56.44                            499                    72.74  
  Ever                                 274                   43.56                            187                    27.26  
  **Alcohol use**                                                                                                            **\<0.001**
  Never                                428                   68.04                            526                    76.68  
  Ever                                 201                   31.96                            160                    23.32  

Two-sided *χ* ^2^ test and student t test; Bold values are statistically significant (*p* \<0.05).

10.1371/journal.pone.0080570.t002

###### Primary information for *hsa-miR-34b/c* rs4938723 T\>C, *pri-miR-124-1* rs531564 C\>G, *pre-miR-125a* rs12975333 G\>T and *hsa-miR-423* rs6505162 C\>A polymorphisms.
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  Genotyped SNPs                                                           *hsa-miR-34b/c* rs4938723 T\>C   *pri-miR-124-1* rs531564 C\>G   *pre-miR-125a* rs12975333 G\>T   *hsa-miR-423* rs6505162 C\>A
  ----------------------------------------------------------------------- -------------------------------- ------------------------------- -------------------------------- ------------------------------
  Chromosome                                                                             11                               8                               19                              17
  Gene Official Symbol                                                                MIR34B/C                        MIR124-1                         MIR125A                          MIR423
  Function                                                                             ncRNA                            ncRNA                           ncRNA                           ncRNA
  Chr Pos (Genome Build 36.3)                                                        110887775                         9798109                         56888340                        25468309
  Regulome DB Score[a](#nt102){ref-type="table-fn"}                                      5                                5                               5                               1f
  TFBS[b](#nt103){ref-type="table-fn"}                                                   Y                                Y                               Y                               Y
  Splicing (ESE or ESS)                                                                 ---                              ---                             ---                              Y
  MAF[c](#nt104){ref-type="table-fn"} for Chinese in database                          0.400                            0.178                          Unknown                          0.200
  MAF in our controls (n = 686)                                                        0.324                            0.157                           0.000                           0.188
  *p* value for HWE[d](#nt105){ref-type="table-fn"}test in our controls                0.675                            0.400                            ---                            0.299
  Genotyping method[e](#nt106){ref-type="table-fn"}                                     LDR                              LDR                             LDR                             LDR
  \% Genotyping value                                                                  96.81%                          96.43%                           96.43%                          95.13%

<http://www.regulomedb.org/>;

TFBS: Transcription Factor Binding Site (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>);

MAF: minor allele frequency;

HWE: Hardy--Weinberg equilibrium;

LDR: Ligation Detection Reaction.

Associations between hsa-miR-34b/c rs4938723 T\>C, pri-miR-124-1 rs531564 C\>G, pre-miR-125a rs12975333 G\>T and hsa-miR-423 rs6505162 C\>A polymorphisms and risk of ESCC {#s3b}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The genotype distributions of *hsa-miR-34b/c* rs4938723 T\>C, *pri-miR-124-1* rs531564 C\>G, *pre-miR-125a* rs12975333 G\>T and *hsa-miR-423* rs6505162 C\>A in the cases and the controls are shown in [Table 3](#pone-0080570-t003){ref-type="table"}. In the single locus analyses, the genotype frequencies of *hsa-miR-34b/c* rs4938723 T\>C were 46.2% (TT), 46.3% (TC), and 7.5% (CC) in the case patients and 46.1% (TT), 43.1% (TC), and 10.8% (CC) in the control subjects, and the difference was not statistically significant (*p* = 0.101). In the recessive model, when the *hsa-miR-34b/c* rs4938723 TT/TC genotypes were used as the reference group, the CC homozygote genotype was associated with a statistically significantly decreased risk for ESCC (CC vs. TT/TC: adjusted OR = 0.65, 95% CI = 0.44--0.97, *p* = 0.036). When the *hsa-miR-34b/c* rs4938723 TT homozygote genotype was used as the reference group, the TC genotype was not associated with the risk for ESCC (TC vs. TT: adjusted OR = 1.11, 95% CI = 0.88--1.40, *p* = 0.397); the CC genotype was not associated with the risk for ESCC (CC vs. TT: adjusted OR = 0.69, 95% CI = 0.45--1.04, *p* = 0.076). In the dominant model, the *hsa-miR-34b/c* rs4938723 TC/CC variants were not associated with the risk for ESCC, compared with the *hsa-miR-34b/c* rs4938723 TT genotype (adjusted OR = 1.02, 95% CI = 0.82--1.28, *p* = 0.853) ([Table 3](#pone-0080570-t003){ref-type="table"}).

10.1371/journal.pone.0080570.t003

###### Logistic regression analyses of associations between *hsa-miR-34b/c* rs4938723 T\>C, *pri-miR-124-1* rs531564 C\>G, *pre-miR-125a* rs12975333 G\>T and *hsa-miR-423* rs6505162 C\>A polymorphisms and risk of ESCC.
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  Genotype                         Cases (n = 629) n %           Controls(n = 686) n %   Crude OR(95%CI)              *p*              Adjusted OR [a](#nt107){ref-type="table-fn"}(95%CI)              *p*             
  ------------------------------- --------------------- ------- ----------------------- ----------------- --------------------------- ----------------------------------------------------- --------------------------- -----------
  *hsa-miR-34b/c*rs4938723 T\>C                                                                                                                                                                                         
  TT                                       277           46.2             310                 46.1                   1.00                                                                              1.00             
  TC                                       278           46.3             290                 43.1             1.07 (0.85--1.35)                              0.551                              1.11 (0.88--1.40)         0.397
  CC                                       45             7.5             73                  10.8             0.69 (0.46--1.04)                              0.073                              0.69 (0.45--1.04)         0.076
  CC vs. TC vs. TT                                                                                                                                                                                                         0.101
  TC+CC                                    323           53.8             363                 53.9             1.00 (0.80--1.24)                              0.970                              1.02 (0.82--1.28)         0.853
  TT+TC                                    555           92.5             600                 89.2                   1.00                                                                              1.00             
  CC                                       45             7.5             73                  10.8         **0.67 (0.45**--**0.98)**                        **0.041**                        **0.65 (0.44**--**0.97)**   **0.036**
  T allele                                 832           69.3             910                 67.6                   1.00                                                                                               
  C allele                                 368           30.7             436                 32.4             0.92 (0.78--1.09)                              0.350                                                     
  *pri-miR-124-1*rs531564 C\>G                                                                                                                                                                                          
  CC                                       454           74.3             470                 71.5                   1.00                                                                              1.00             
  CG                                       146           23.9             168                 25.6             0.90 (0.70--1.16)                              0.726                              0.96 (0.74--1.25)         0.768
  GG                                       11             1.8             19                   2.9             0.60 (0.28--1.27)                              0.183                              0.63 (0.29--1.36)         0.237
  GG vs. CG vs. CC                                                                                                                                                                                                         0.319
  CG+GG                                    157           25.7             187                 28.5             0.87 (0.68--1.11)                              0.269                              0.93 (0.72--1.19)         0.559
  CC+CG                                    600           98.2             638                 97.1                   1.00                                                                              1.00             
  GG                                       11             1.8             19                   2.9             0.62 (0.29--1.30)                              0.205                              0.64 (0.30--1.37)         0.245
  C allele                                1054           86.3            1108                 84.3                   1.00                                                                                               
  G allele                                 168           13.7             206                 15.7             0.86 (0.69--1.07)                              0.171                                                     
  *pre-miR-125a*rs12975333 G\>T                                                                                                                                                                                         
  GG                                       611           100.0            657                 100.0                  1.00                                                                              1.00             
  GT                                        0             0.0              0                   0.0                    ---                                      ---                                      ---                 ---
  TT                                        0             0.0              0                   0.0                    ---                                      ---                                      ---                 ---
  *hsa-miR-423*rs6505162 C\>A                                                                                                                                                                                           
  CC                                       374           62.3             425                 65.3                   1.00                                                                              1.00             
  CA                                       197           32.8             207                 31.8             1.08 (0.85--1.37)                              0.522                              1.09 (0.86--1.40)         0.476
  AA                                       29             4.8             19                   2.9             1.73 (0.96--3.14)                              0.070                              1.70 (0.92--3.12)         0.089
  AA vs. CA vs. CC                                                                                                                                                                                                         0.173
  CA+AA                                    226           37.7             226                 34.7             1.14 (0.90--1.43)                              0.278                              1.14 (0.90--1.45)         0.264
  CC+CA                                    571           95.2             632                 97.1                   1.00                                                                              1.00             
  AA                                       29             4.8             19                   2.9             1.69 (0.94--3.05)                              0.081                              1.65 (0.90--3.01)         0.106
  C allele                                 945           78.8            1057                 81.2                   1.00                                                                                               
  A allele                                 255           21.3             245                 18.8             1.16 (0.96--1.42)                              0.128                                                     

Adjusted for age, sex, smoking status and alcohol consumption.

No association was observed between *pri-miR-124-1* rs531564 C\>G and *hsa-miR-423* rs6505162 C\>A polymorphisms and the risk of ESCC ([Table 3](#pone-0080570-t003){ref-type="table"}). For *pre-miR-125a* rs12975333 G\>T, all genotypes are GG homozygotes ([Table 3](#pone-0080570-t003){ref-type="table"}).

Stratification analyses of hsa-miR-34b/c rs4938723 T\>C, pri-miR-124-1 rs531564 C\>G and hsa-miR-423 rs6505162 C\>A and risk of ESCC {#s3c}
------------------------------------------------------------------------------------------------------------------------------------

To evaluate the effects of *hsa-miR-34b/c* rs4938723 T\>C, *pri-miR-124-1* rs531564 C\>G and *hsa-miR-423* rs6505162 C\>A genotypes on ESCC risk according to different age, sex, smoking and alcohol drinking status; we performed the stratification analyses ([Table 4](#pone-0080570-t004){ref-type="table"}). A significantly decreased risk of ESCC associated with the *hsa-miR-34b/c* rs4938723 T\>C polymorphism was evident among patients who never drinking (CC vs. TT/TC: adjusted OR = 0.57, 95% CI = 0.34--0.94, *p* = 0.029) ([Table 4](#pone-0080570-t004){ref-type="table"}). In patients who smoking, *hsa-miR-423* rs6505162 C\>A might associated with a significantly increased risk of ESCC (AA vs. CC/CA: adjusted OR = 4.94, 95% CI = 1.42--17.21, *p* = 0.012) ([Table 4](#pone-0080570-t004){ref-type="table"}).

10.1371/journal.pone.0080570.t004

###### Stratified analyses between *hsa-miR-34b/c* rs4938723 T\>C, *pri-miR-124-1* rs531564 C\>G and *hsa-miR-423* rs6505162 C\>A polymorphism and ESCC risk by sex, age, smoking status and alcohol consumption.
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  Variable               *hsa-miR-34b/c* rs4938723 T\>C (case/control)   Adjusted OR (95% CI) [a](#nt108){ref-type="table-fn"}   *pri-miR-124-1* rs531564 C\>G (case/control)   Adjusted OR (95% CI)   *hsa-miR-423* rs6505162 C\>A (case/control)   Adjusted OR (95% CI)                                                     
  --------------------- ----------------------------------------------- ------------------------------------------------------- ---------------------------------------------- ---------------------- --------------------------------------------- ---------------------- ------ ------------------ --------- ------- ------ ---------------------------
  Sex                                                                                                                                                                                                                                                                                                                         
  Male                                      396/402                                              32/47                                               1.00                         0.68(0.42--1.10)                       420/430                             9/14           1.00   0.69(0.29--1.63)   402/419   24/16   1.00       1.54(0.79--2.98)
  Female                                    159/198                                              13/26                                               1.00                         0.60(0.30--1.21)                       180/208                             2/5            1.00   0.51(0.10--2.67)   169/213    5/3    1.00       2.26(0.53--9.66)
  Age                                                                                                                                                                                                                                                                                                                         
  \<63                                      274/319                                              20/37                                               1.00                         0.64(0.35--1.15)                       297/333                             4/14           1.00   0.35(0.11--1.11)   278/333   16/12   1.00       1.75(0.79--3.86)
  ≥63                                       281/281                                              25/36                                               1.00                         0.68(0.39--1.16)                       303/305                             7/5            1.00   1.33(0.41--4.31)   293/299   13/7    1.00       1.91(0.74--4.94)
  Smoking status                                                                                                                                                                                                                                                                                                              
  Never                                     309/441                                              24/51                                               1.00                         0.62(0.37--1.04)                       341/460                             6/14           1.00   0.68(0.26--1.79)   327/456   10/16   1.00       0.96(0.42--2.20)
  Ever                                      246/159                                              21/22                                               1.00                         0.69(0.36--1.30)                       259/178                             5/5            1.00   0.74(0.21--2.64)   244/176   19/3    1.00   **4.94(1.42**--**17.21)**
  Alcohol consumption                                                                                                                                                                                                                                                                                                         
  Never                                     379/465                                              25/54                                               1.00                       **0.57(0.34--0.94)**                     408/486                             8/14           1.00   0.77(0.31--1.91)   391/484   16/15   1.00       1.41(0.66--2.99)
  Ever                                      176/135                                              20/19                                               1.00                         0.79(0.39--1.57)                       192/152                             3/5            1.00   0.50(0.12--2.17)   180/148   13/4    1.00       3.00(0.94--9.57)

Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model; Bold values are statistically significant (*p* \<0.05).

Discussion {#s4}
==========

In this hospital-based case-control study of ESCC, we investigated the associations of *hsa-miR-34b/c* rs4938723 T\>C, *pri-miR-124-1* rs531564 C\>G, *pre-miR-125a* rs12975333 G\>T and *hsa-miR-423* rs6505162 C\>A with risk of ESCC in a high risk Chinese population. Our multivariable logistic analysis revealed that *hsa-miR-34b/c* rs4938723 CC genotype had a decreased risk of ESCC. The association was evident among patients who never drinking. *Hsa-miR-423* rs6505162 C\>A might associated with a significantly increased risk of ESCC in patients who smoking.

It is well known that members of the miR-34 family expression is directly induced by p53 in response to DNA damage or oncogenic stress [@pone.0080570-Bommer1]. A rat model experiment indicated that the alteration of miR-34b/c under an inflammatory microenvironment can be influenced by p53 [@pone.0080570-Mathe1]. By DNA methylation of its own promoter, miR-34 family has been silenced in numerous cancers [@pone.0080570-Vogt1]. By triggering Wnt signaling cascades, the loss of miR-34 impairs p53-mediated cell death. Overexpression of miR-34 can induce apoptosis [@pone.0080570-He1]--[@pone.0080570-Kim1]. The role of miR-34a in the suppression of tumor growth has also been detected in vivo [@pone.0080570-Tazawa1]. In a previous study, down-regulation of mir-34b/c by methylation was found in colorectal cancer [@pone.0080570-Toyota1], oral cancer [@pone.0080570-Kozaki1] and malignant melanoma [@pone.0080570-Lujambio1]. The *hsa-miR-34b/c* rs4938723 T\>C SNP is located within the CpG island of pri-miR-34b/c and may affect a predicted GATA-X transcription factor binding [@pone.0080570-Son1]. *Hsa-miR-34b/c* rs4938723 T\>C polymorphism was associated with the risk of nasopharyngeal carcinoma [@pone.0080570-Li1], hepatocellular carcinoma [@pone.0080570-Han1], colorectal cancer [@pone.0080570-Gao1] and breast cancer survival [@pone.0080570-Bensen1]. *Hsa-miR-423* rs6505162 C\>A polymorphism was associated with reduced breast cancer risk [@pone.0080570-Smith1] and both the overall survival and the recurrence-free survival of colorectal cancer [@pone.0080570-Xing1]. In our study, we found *hsa-miR-34b/c* rs4938723 CC genotype had a decreased risk of ESCC among patients who never drinking, *hsa-miR-423* rs6505162 C\>A might associated with a significantly increased risk of ESCC in patients who smoking, indicating gene-environment interaction.

The frequencies of genetic polymorphisms often vary between ethnic groups. In the present Chinese study, the allele frequency of *hsa-miR-34b/c* rs4938723 C was 0.324 among 686 control subjects, which is slightly higher than that of Japanese population (0.261) and similar to that of European population (0.310) and Sub-Saharan African population (0.305). The allele frequency of *hsa-miR-423* rs6505162 A was 0.188 among 686 control subjects, which is in accordance with that of Chinese population (0.200) and Japanese population (0.178). But the allele frequency is significantly lower than that of European population (0.575) and Sub-Saharan African population (0.783) (<http://www.ncbi.nlm.nih.gov/SNP>, <http://hapmap.ncbi.nlm.nih.gov/>).

Using Power and Sample Size Calculation (PS, version 3.0, 2009, <http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>), considering *hsa-miR-34b/c* rs4938723 T\>C mutant alleles in the control group, OR, ESCC samples and control samples, the power of our analysis (α = 0.05) was 0.929 in 600 ESCC cases and 673 controls with adjusted OR 0.65. The power of our analysis (α = 0.05) was 0.962 in 404 ESCC cases and 519 controls with adjusted OR 0.57 in non- drinking subgroup. For *hsa-miR-423* rs6505162 C\>A, the power of our analysis (α = 0.05) was 1.000 in 263 ESCC cases and 179 controls with adjusted OR 4.94 in smoking subgroup.

In this case-control study, several limitations need to be addressed. Firstly, the patients and controls were enrolled from hospitals and may not represent the general population. Secondly, statistical power of our study was limited the especially in stratification analyses, it is better that the control group being larger than the case group; therefore it is possible to have a more statistical power. Thirdly, detailed information on cancer metastasis and survival were not recruited till now, which restricted further analyses on the role of the four polymorphisms in ESCC progression and prognosis. Finally, the information about viral infections and immune parameters was not available, which restricted the power of our analyses.

In conclusion, our study provides evidence that functional polymorphisms *hsa-miR-34b/c* rs4938723 T\>C and *hsa-miR-423* rs6505162 C\>A might alter individual susceptibility to ESCC. Future larger studies with other ethnic populations and functional analysis are required to confirm current findings.
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